Nektar Therapeutics to Present at Jefferies Global Healthcare Conference
Event summary
- Nektar Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference on June 3, 2026.
- The company will host a fireside chat webcast at 1:20 p.m. Eastern Time.
- Nektar's lead product candidate, rezpegaldesleukin (REZPEG), is in Phase 2b trials for atopic dermatitis and alopecia areata, and Phase 2 for Type 1 diabetes mellitus.
- The company's pipeline includes preclinical programs NKTR-0165, NKTR-0166, and NKTR-422.
The big picture
Nektar Therapeutics' participation in the Jefferies Global Healthcare Conference comes at a critical juncture as it advances its lead candidate through late-stage trials. The company's focus on regulatory T cell stimulation positions it in a niche segment of the autoimmune disease market, where success could drive significant valuation uptick. Investors will be watching closely for updates on trial progress and pipeline advancements.
What we're watching
- Clinical Progress
- How the Phase 2b trial results for rezpegaldesleukin in atopic dermatitis and alopecia areata will impact Nektar's valuation.
- Pipeline Development
- Whether the preclinical programs NKTR-0165 and NKTR-0166 will advance to clinical trials within the next 12 months.
- Market Positioning
- The pace at which Nektar can differentiate itself in the competitive autoimmune and chronic inflammatory disease space.
Related topics